Can the Rapid Antigen Test for COVID-19 Replace RT-PCR: A Meta-analysis of Test Agreement

Ibrahim Elmakaty^{*1}, Abdelrahman Elsayed^{*1}, Rama Ghassan Hommos^{*1}, Ruba Abdo^{*1}, Amira Mohamed¹, Zahra Yousif¹, Maryam Fakhroo¹, Abdulrahman Alansari¹, Peter V. Coyle², Suhail A. R. Doi^{#3}

¹Fourth-year Medical Students, Department of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.

²Senior Consultant and Head of Virology, Hamad General Hospital, Doha, Qatar.

³Professor of Clinical Epidemiology and Head of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.

*Contributed equally [#]Correspondence to: Professor Suhail A. R. Doi, Department of Population Medicine, College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar Tel.: +974 66001271 Email: sdoi@qu.edu.qa

Summary

Background

Several studies have compared the performance of reverse transcription-polymerase chain reaction (RT-PCR) and antigen rapid diagnostic tests (Ag-RDTs) as tools to diagnose SARS-CoV-2 disease (COVID-19). As the performance of Ag-RDT may vary among different products and viral load scenarios, the clinical utility of the Ag-RDT remains unclear. Our aim is to assess the diagnostic agreement between Ag-RDTs and RT-PCR in testing for COVID-19 across different products and cycle threshold (Ct) values.

Methods

An evidence synthesis and meta-analysis of Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) was conducted after an exhaustive search of five databases to locate published studies that compared Ag-RDT to RT-PCR and reported quantitative comparison results. After the screening, quality assessment, and data extraction, the synthesis of pooled estimates was carried out utilizing the quality-effects (QE) model and Freeman-Tukey double arcsine transformation (FTT) for variance stabilization. Subgroup analysis was also conducted to evaluate the tests' diagnostic agreement across distinctive products and Ct-value thresholds.

Findings

A total of 420 studies were screened by title and abstract, of which 39 were eventually included in the analysis. The overall NPA was 99.4% (95%CI 98.8-99.8, I^2 =91.40%). The PPA was higher in lower Ct groups such as groups with Ct <20 and Ct <25, which had an overall PPA of 95.9% (95%CI 92.7-98.2, I^2 =0%) and 96.8% (95%CI 95.2-98.0, I^2 =50.1%) respectively. This is in contrast to groups with higher Ct values, which had relatively lower PPA. Panbio and Roche Ag-RDTs had the best consistent overall PPA across different Ct groups especially in groups with Ct <20 and Ct <25.

Interpretation

The findings of our meta-analysis support the use of Ag-RDTs in lieu of RT-PCR for decision making regarding COVID-19 control measures, since the enhanced capacity of RT-PCR to detect disease in those that are Ag-RDT negative will be unlikely to have much public health utility. This step will drastically reduce the cost and time in testing for COVID-19.

Funding

This research did not receive any specific funding.

Introduction:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged as a novel human pathogen in China at the end of 2019, is responsible for coronavirus disease 2019 (COVID-19). It causes symptoms such as cough, fever, and severe pneumonia. The World Health Organisation (WHO) reported more than 200 million cases of COVID-19, including approximately 5 million deaths as of the 7th of October 2021.¹ The reference test for COVID-19 diagnosis is reverse transcriptionpolymerase chain reaction (RT-PCR) using nasopharyngeal or oropharyngeal swabs.² It is designed to detect viral RNA and has high sensitivity and specificity.³ Contrarily, COVID-19 antigen-detection rapid diagnostic tests (Ag-RDTs) diagnose active infection by detecting SARS-CoV-2 viral proteins in upper respiratory swabs samples. Unlike RT-PCR, Antigen tests produce results in 15 to 30 minutes. In addition, they are cheaper, don't require specialized laboratory personnel, and can be produced in larger quantities for large-scale deployment.⁴

Several studies have compared RT-PCR and Ag-RDTs as tools to diagnose COVID-19 infection. Studies differ in conclusions with some concluding that there is an overall excellent agreement between the two tests.^{5,6} In contrast, other studies suggest that Ag-RDT is not reliable enough to be used alone for COVID-19 diagnosis.⁷ In addition, the performance of Ag-RDT can vary among different products and viral loads. Different studies have stratified the patients into separate groups based on the Ct-values to try to account for viral load. Despite this, there has not been much consensus on the use of the Ag-RDT and thus this synthesis aims to evaluate Ag-RDTs diagnostic agreement across different products and viral load scenarios in comparison to RT-PCR, in order to make firm recommendations on its utility. This would be essential for enhancing control measures in the current pandemic.

There have been several previous attempts at evidence synthesis but, to our knowledge, all previous syntheses⁸⁻¹² used diagnostic accuracy synthesis methods with RT-PCR designated as a gold standard and computed sensitivity, specificity, and other diagnostic indices. This may have lengthened this debate for two reasons: First, and most important, the synthesis method is completely different. Bivariate synthesis of sensitivity and specificity was used to account for their inverse correlation versus univariate synthesis of Positive Percent Agreement (PPA) and

Negative Percent Agreement (NPA) in this paper. Second, the diagnostic accuracy perspective tends to then lead on to post-test probability concerns that are not really warranted and may make the interpretation of the applicability of Ag-RDTs difficult. Our meta-analysis is the first to assess the performance of Ag-RDT under the qualitative test framework suggested by the Clinical and Laboratory Standards Institute (CLSI).¹³

Methods:

Search strategy and selection criteria

This was a rapidly performed evidence synthesis and meta-analysis; therefore, protocol registration was not deemed appropriate. An extensive search strategy was designed to retrieve all relevant articles published in PubMed up to 15 Mar 2021, using the following MeSH terms: "COVID-19" AND "Immunoassay" AND "Reverse Transcriptase Polymerase Chain Reaction". To ensure comprehensiveness, other databases such as Embase, Google Scholar, EBSCO, and Scopus were similarly searched for additional relevant articles. No restrictions were imposed on searches, and duplicate articles were removed without the use of an automation tool. This study was reported in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.¹⁴

The records that were obtained from the literature search were further considered through screening of titles and abstracts using the Rayyan platform.¹⁵ Two reviewers independently screened papers and any disagreements were resolved by consensus involving the whole team. The full texts of studies deemed potentially eligible were then retrieved and double-screened independently, with referral to a co-reviewer in case of a discrepant judgment.

We adopted broad eligibility criteria and included studies that used Ag-RDT as their index test, RT-PCR as their reference test to detect COVID-19, and reported the values of Ag-RDT positives among RT-PCR positives, and Ag-RDT negatives among RT-PCR negatives. Studies that did not meet these inclusion criteria were excluded. We excluded studies where PPA and NPA could not be computed as well as literature reviews, recommendation studies, and studies not available in English.

Data analysis

We extracted data from each eligible study on study design, study population, swab source, reference test, index test, and the number of positive Ag-RDT tests among positive RT-PCR and negative Ag-RDT tests among negative RT-PCR. All data were extracted into an excel worksheet (supplementary).

The Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS-2)¹⁶ was used to assess the methodological quality of selected articles, which was also done in an independent manner by two reviewers with the consultation of a third reviewer if needed. Even though this tool may not apply directly to diagnostic agreement studies, it was the closest in context and still provided an indication of the relative ranking of studies in terms of their methodological rigour. We deemed the relevant questions in the tool to refer to safeguards against bias, then counted the number of safeguards implemented in each study rather than assessing the risk of bias as a judgment as recommended by the tool.¹⁶ Thus, a numeric value of 1 was given if implemented ("yes/low bias"), and 0 if not implemented ("no/high bias/unclear"). This was done to allow the quality assessment to have quantitative utility¹⁷ for input into a bias-adjusted meta-analysis model.¹⁸ Besides excluding all judgment questions, we also excluded the following safeguard: "Is the reference standard likely to correctly classify the target condition?" as it did not apply to this agreement study.

The quality-effects (QE) model^{19,20} was utilized for bias-adjusted synthesis using the results of the quality assessment as relative ranks.²¹ The QE model accounts for methodological quality-related heterogeneity by redistributing study weights by quality rank, thus bias adjusting the synthesis.^{19,20} Pooled estimated PPA and NPA along with their 95% confidence intervals (95%CI) were calculated after utilizing the Freeman-Tukey double arcsine transformation (FTT)²² to stabilize the variance since double arcsine transformation has better performance in the synthesis of proportions.²³ All results were back-transformed to proportions and converted to percentages for reporting. Heterogeneity was evaluated using the l² statistic,²⁴ while publication bias and possible small study effects were assessed by Doi plots, and the Doi plot symmetry was quantified using the LFK index.²⁵ All analysis, graphs, and plots were undertaken using Stata version 16²⁶ after installing the *metan* module²⁷ as recently recommended.²⁸

To compare Ag-RDT results across products and distinctive Ct-value thresholds, five groups were created according to Ct-values ranges. The first three groups are comprehensive ranges that altogether contain all Ct-values. Group one is Ct <20,

group two is any range from 20 to 30 cycles, while group three is Ct >30. The fourth group included data restricted to Ct <25, while group five was restricted to Ct <30 (table 1). Ag-RDTs were also classified into separate groups by the product to identify which one had the best performance. A product was analysed individually only if it had five data sets or more by Ct-value group otherwise it was added into a combined products' group called "other" (supplementary).

Role of the funding source

None.

Results:

The selection process of studies is depicted in a PRISMA flowchart (figure 1).¹⁴ Our search strategy yielded 416 studies and simultaneous search on other databases yielded 61 additional studies. 57 duplicates were identified and removed leaving a total of 420 studies that had undergone screening by title and abstract. Of which, 65 studies were assessed further for eligibility using their full-text articles. Only 39 studies were finally selected for inclusion in the analysis. The rest of the studies were excluded for reasons that are shown in the PRISMA chart.

The characteristics of included studies are presented in table 2. The included studies came from various countries with the greatest number of studies from the USA (n=8), followed by Spain (n=6), and Japan (n=6). Participants in the included studies varied from being either symptomatic only (n=9), asymptomatic only (n=2), or a mix of both (n=25). The rest of the studies (n=3) and a subgroup in one of the studies⁶¹ did not provide information regarding the participant's symptom status. One study was performed among pediatric patients only,⁴⁴ while another study had a subgroup of pediatric patients that were analysed separately.³⁸ One study had no information regarding the participants' ages.⁶⁶ The rest of the studies (n=36) had either adults only or participants of all ages. Three studies are reported as a and b (supplementary) based on either the participants' age,³⁸ methodology of participants selection,⁶¹ or the site where the sample collection took place.⁶³ Some studies (n=4) have tested more than one Ag-RDT on the same cohort of patients, two studies had four Ag-RDTs,^{53,59} one had three Ag-RDTs,⁵¹ and two had two Ag-RDTs.^{41,62}

Meta-analysis results

Since NPA is an estimate of COVID-19 negative population and is not expected to change across different Ct-value ranges, therefore only NPA at detection threshold is considered. Figure 2 summarizes the NPA results of different Ag-RDTs across all products. The analysis showed that the overall NPA was 99.4% (95%CI 98.8-99.8, I²=91.40%). There was negative asymmetry on the Doi plot (LFK index=-3.81; supplementary) suggesting that more of the smaller studies had a lower NPA. Despite the latter, NPA ranged from 99.9% (95%CI 99.7-100) to 97.9% (95%CI 91.9-100) for BinaxNOW and Lumipulse respectively, indicating high and consistent NPA values across products despite a downward bias from small studies.

Figure 3 summarizes the PPA findings. The analysis showed better PPA values in groups with lower Ct-values (higher viral load). The overall PPA in the group with Ct <20 was 95.9% (95%CI 92.7-98.2, I^2 =0%) and the Doi plot suggested minor negative asymmetry (LFK= -1.29; supplementary). Similarly, the overall PPA of the group with Ct <25 was 96.8% (95%CI 95.2-98.0, I^2 =50.1%; figure 4) with minor negative asymmetry (LFK=-1.73; supplementary). As the Ct-value increases in groups with Ct <30 and Ct >30, the PPA drops significantly to 77.1% (95% CI 69.5- 83.9, I^2 = 95.9%) and 38.6% (95% CI 12.9-67.7, I^2 =95.9%), respectively. There was only major negative asymmetry for Ct >30 group suggesting that some small studies had extremely low PPA values.

Regarding the PPA of particular products, the PPA of Panbio and Roche Ag-RDTs were the most consistent across clinically important groups such as group one and four (see figure 3).

Discussion:

The clear presence of an inverse relationship between the Ct value of a patient group and the PPA of Ag-RDT was demonstrated by our results (figure 5). What has not till now been clarified is where the PPA threshold lies, and we show this to be at Ct <25 with Panbio and Roche being the products demonstrating the highest PPA of 96.1% (95%Cl 91.9-98.9) and 97.4% (95%Cl 92.9-99.8), respectively.

Beyond a Ct value of 25, the concordance of a positive Ag-RDT with RT-PCR declines. This drop-off may actually be an advantage rather than a limitation of the Ag-RDT since it has been reported that high Ct-value has a reduced chance of successful culture and of being contagious,⁶⁸ which has been shown to be between Ct ranging from 24–30.^{69,70} This suggests that individuals start being more

contagious at the threshold where the Ag-RDT operates best. Therefore, in case an Ag-RDT fails to detect an infected individual of Ct >25, it is likely that the individual is either noncontagious or is in early infection, which can be resolved by re-testing on subsequent days for contacts of a documented case.

In our study, we considered the RT-PCR to be a reference test, rather than a gold standard as done by previous meta-analyses targeting the same topic. This makes our study the first meta-analysis to have presented the PPA and NPA of Ag-RDTs, which is a primary strength of this study and allows interpretation of results for decision-makers. In addition, we used robust methodologies¹⁹ and broad yet specific selection criteria. It is also important to note that although this is an agreement study, we have found QUADAS-2¹⁶ to be suitable for quality assessment of diagnostic agreement studies with only the exclusion of a single safeguard.

There are a few limitations to our meta-analysis that should be mentioned. To begin with, not enough studies have stratified their analysis based on Ct-value, which resulted in data limitation clearly shown in our results. An example would be the low number of studies per product in group 1 (Ct <20), in which case we did not stratify by product in that group. Furthermore, most of the studies were earlier studies that evaluated patients with the classic variant of SARS-CoV-2 and thus tests should be selected based on the manufacturer having approved these for use with the newer variants of the virus.

The results of this study have several implications for practice. First, we recommend the use of Ag-RDT for trace and test procedures in the current pandemic thus replacing RT-PCR. Second, we suggest prioritizing Panbio[™] COVID-19 Ag Rapid Test or Roche SARS-CoV-2 Rapid Antigen Test until further data is available or where local validation supports alternatives. Third, each health system must crosscheck results with variants under circulation and must make sure that the manufacturer actually has considered this in the product development and its futureproofing as is the norm for RT-PCR assays. This change is expected to result in huge cost and time savings for health systems worldwide and avoid quarantine of Ag-RDT in asymptomatic patients in the first 5 days of contact as well as for screening purposes in public settings, such as sports matches or airports. This recommendation is in conformity with multiple studies showing high Ag-RDT performance in asymptomatic individuals with low viral loads.^{30,32,36} Finally, we

suggest that manufacturers consider scaling up the use of Ag-RDTs by making them applicable to batch in large numbers, then have their results electronically transmitted to hospital information systems. This does not mean that point of care testing should be abandoned, but rather that there be a choice depending on what use is to be made of the test.

Contributors

IE*, AE*, RGH*, RA*, AM, ZY, MF, and SAD provided critical conceptual input. SAD designed the methodology. IE*, AE*, and SAD performed the formal analysis. IE*, AE*, RGH*, RA*, PVC, and SAD validated the results of the study. IE*, AE*, RGH*, RA*, AM, ZY, MF, and AA were involved in the investigation, data curation, and writing the original draft. IE*, AE*, RGH*, RA*, AM, ZY, MF, PVC, and SAD reviewed and edited the report. RGH* was the administrator, and supervised this work along with SAD and PVC.

*Contributed equally to this report.

Declaration of interests

The authors report no conflict of interest. PVC and SAD are members of the Scientific Research and Reference Taskforce on COVID-19 of the Ministry of Public Health in the State of Qatar.

Data sharing

The data used for analysis in this study is available from the corresponding author on reasonable request.

References:

1 Coronavirus disease (COVID-19) – World Health Organization. Who.int. 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-

2019?gclid=CjwKCAjwmqKJBhAWEiwAMvGt6G7TPITmKqK4wb3kl0p0vb4wtMcvJjB CxkUPyc0KnIgi8jSFnJ_SGRoCcxkQAvD_BwE (accessed 9 October 2021).

2 Bustin S, Nolan T. RT-qPCR Testing of SARS-CoV-2: A Primer. International Journal of Molecular Sciences 2020; 21: 3004.

3 Esbin M, Whitney O, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. RNA 2020; 26: 771-783.

4 Peeling R, Olliaro P, Boeras D, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. The Lancet Infectious Diseases 2021; 21: e290-e295.

5 Pujadas E, Ibeh N, Hernandez M et al. Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test. Journal of Medical Virology 2020; 92: 1695-1698.

6 Beck E, Paar W, Fojut L, Serwe J, Jahnke R. Comparison of the Quidel Sofia SARS FIA Test to the Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients. Journal of Clinical Microbiology 2021; 59. DOI:10.1128/jcm.02727-20.

7 Eshghifar N, Busheri A, Shrestha R, Beqaj S. Evaluation of Analytical Performance of Seven Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus. International Journal of General Medicine 2021; Volume 14: 435-440.

8 Brümmer L, Katzenschlager S, Gaeddert M et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and metaanalysis. PLOS Medicine 2021; 18: e1003735.

9 Castro R, Luz P, Wakimoto M, Veloso V, Grinsztejn B, Perazzo H. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. The Brazilian Journal of Infectious Diseases 2020; 24: 180-187.

10 Dinnes J, Deeks J, Berhane S et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database of Systematic Reviews 2021; 2021. DOI:10.1002/14651858.cd013705.pub2.

11 Hayer J, Kasapic D, Zemmrich C. Real-world clinical performance of commercial SARS-CoV-2 rapid antigen tests in suspected COVID-19: A systematic meta-analysis of available data as per November 20, 2020. 2020. DOI:10.1101/2020.12.22.20248614.

12 Khandker S, Nik Hashim N, Deris Z, Shueb R, Islam M. Diagnostic Accuracy of Rapid Antigen Test Kits for Detecting SARS-CoV-2: A Systematic Review and Meta-Analysis of 17,171 Suspected COVID-19 Patients. Journal of Clinical Medicine 2021; 10: 3493.

13 Garrett P, Lasky F, Meier K, Clark L. User protocol for evaluation of qualitative test performance. Wayne, Pa.: Clinical and Laboratory Standards Institute, 2008.

14 Moher D, Liberati A, Tetzlaff J, Altman D. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 2009; 6: e1000097.

15 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews 2016; 5. DOI:10.1186/s13643-016-0384-4.

16 Whiting P. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Annals of Internal Medicine 2011; 155: 529.

17 Furuya-Kanamori L, Xu C, Hasan S, Doi S. Quality versus Risk-of-Bias assessment in clinical research. Journal of Clinical Epidemiology 2021; 129: 172-175.

18 Stone J, Glass K, Munn Z, Tugwell P, Doi S. Comparison of bias adjustment methods in meta-analysis suggests that quality effects modeling may have less limitations than other approaches. Journal of Clinical Epidemiology 2020; 117: 36-45. 19 Doi S, Thalib L. A Quality-Effects Model for Meta-Analysis. Epidemiology 2008; 19: 94-100.

20 Doi S, Barendregt J, Khan S, Thalib L, Williams G. Advances in the metaanalysis of heterogeneous clinical trials II: The quality effects model. Contemporary Clinical Trials 2015; 45: 123-129.

21 Stone J, Gurunathan U, Aromataris E et al. Bias Assessment in Outcomes Research: The Role of Relative Versus Absolute Approaches. Value in Health 2021; 24: 1145-1149.

Freeman M, Tukey J. Transformations Related to the Angular and the Square Root. The Annals of Mathematical Statistics 1950; 21: 607-611.

23 Barendregt J, Doi S, Lee Y, Norman R, Vos T. Meta-analysis of prevalence. Journal of Epidemiology and Community Health 2013; 67: 974-978.

Higgins J. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.

25 Furuya-Kanamori L, Barendregt J, Doi S. A new improved graphical and quantitative method for detecting bias in meta-analysis. International Journal of Evidence-Based Healthcare 2018; 16: 195-203.

26 StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC

27 Fisher, D., Harris, R., Bradburn M. et al. (2006). METAN: Stata module for fixed and random effects meta-analysis. Statistical Software Components S456798, Boston College Department of Economics, revised 17 Aug 2021.

28 Doi S, Xu C. The Freeman–Tukey double arcsine transformation for the meta-analysis of proportions: Recent criticisms were seriously misleading. Journal of Evidence-Based Medicine 2021. DOI:10.1111/jebm.12445.

29 Peña-Rodríguez M, Viera-Segura O, García-Chagollán M et al. Performance evaluation of a lateral flow assay for nasopharyngeal antigen detection for SARS-CoV-2 diagnosis. Journal of Clinical Laboratory Analysis 2021; 35. DOI:10.1002/jcla.23745.

30 Pilarowski G, Lebel P, Sunshine S et al. Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco. The Journal of Infectious Diseases 2021; 223: 1139-1144. 31 Pollock N, Jacobs J, Tran K et al. Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts. Journal of Clinical Microbiology 2021; 59. DOI:10.1128/jcm.00083-21.

32 Pilarowski G, Marquez C, Rubio L et al. Field Performance and Public Health Response Using the BinaxNOWTM Rapid Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection Assay During Community-Based Testing. Clinical Infectious Diseases 2020. DOI:10.1093/cid/ciaa1890.

Albert E, Torres I, Bueno F et al. Field evaluation of a rapid antigen test (Panbio[™] COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clinical Microbiology and Infection 2021; 27: 472.e7-472.e10.

34 Aoki K, Nagasawa T, Ishii Y et al. Evaluation of clinical utility of novel coronavirus antigen detection reagent, Espline® SARS-CoV-2. Journal of Infection and Chemotherapy 2021; 27: 319-322.

35 Aoki K, Nagasawa T, Ishii Y et al. Clinical validation of quantitative SARS-CoV-2 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs. Journal of Infection and Chemotherapy 2021; 27: 613-616.

Bulilete O, Lorente P, Leiva A et al. Panbio[™] rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care. Journal of Infection 2021; 82: 391-398.

37 Ristić M, Nikolić N, Čabarkapa V, Turkulov V, Petrović V. Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia. PLOS ONE 2021; 16: e0247606.

38 Möckel M, Corman V, Stegemann M et al. SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department. Biomarkers 2021; 26: 213-220.

39 Merino P, Guinea J, Muñoz-Gallego I et al. Multicenter evaluation of the Panbio[™] COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection 2021; 27: 758-761.

40 Nalumansi A, Lutalo T, Kayiwa J et al. Field evaluation of the performance of a SARS-CoV-2 antigen rapid diagnostic test in Uganda using nasopharyngeal samples. International Journal of Infectious Diseases 2021; 104: 282-286.

41 Osterman A, Baldauf H, Eletreby M et al. Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. Medical Microbiology and Immunology 2021; 210: 65-72.

42 Okoye N, Barker A, Curtis K et al. Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting. Journal of Clinical Microbiology 2021; 59. DOI:10.1128/jcm.03282-20.

43 Young S, Taylor S, Cammarata C et al. Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. Journal of Clinical Microbiology 2020; 59. DOI:10.1128/jcm.02338-20.

Villaverde S, Domínguez-Rodríguez S, Sabrido G et al. Diagnostic Accuracy of the Panbio Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Rapid Test Compared with Reverse-Transcriptase Polymerase Chain Reaction Testing of Nasopharyngeal Samples in the Pediatric Population. The Journal of Pediatrics 2021; 232: 287-289.e4.

45 Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. Journal of Clinical Virology 2020; 129: 104455.

46 Porte L, Legarraga P, Iruretagoyena M et al. Evaluation of two fluorescence immunoassays for the rapid detection of SARS-CoV-2 antigen—new tool to detect infective COVID-19 patients. PeerJ 2021; 9: e10801.

47 Porte L, Legarraga P, Vollrath V et al. Evaluation of Novel Antigen-Based Rapid Detection Test for the Diagnosis of SARS-CoV-2 in Respiratory Samples. SSRN Electronic Journal 2020. DOI:10.2139/ssrn.3569871.

48 Pray I, Ford L, Cole D et al. Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses — Wisconsin, September–October 2020. MMWR Morbidity and Mortality Weekly Report 2021; 69: 1642-1647.

49 Pérez-García F, Romanyk J, Gómez-Herruz P et al. Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection. Journal of Clinical Virology 2021; 137: 104781.

50 Prince-Guerra J, Almendares O, Nolen L et al. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020. MMWR Morbidity and Mortality Weekly Report 2021; 70: 100-105.

51 Jääskeläinen A, Ahava M, Jokela P et al. Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection. Journal of Clinical Virology 2021; 137: 104785.

52 Kobayashi R, Murai R, Asanuma K, Fujiya Y, Takahashi S. Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen. Journal of Infection and Chemotherapy 2021; 27: 800-807.

53 Kohmer N, Toptan T, Pallas C et al. The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. Journal of Clinical Medicine 2021; 10: 328.

54 Krüttgen A, Cornelissen C, Dreher M, Hornef M, Imöhl M, Kleines M. Comparison of the SARS-CoV-2 Rapid antigen test to the real star Sars-CoV-2 RT PCR kit. Journal of Virological Methods 2021; 288: 114024.

55 Linares M, Pérez-Tanoira R, Carrero A et al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology 2020; 133: 104659.

56 Chaimayo C, Kaewnaphan B, Tanlieng N et al. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. Virology Journal 2020; 17. DOI:10.1186/s12985-020-01452-5.

57 Courtellemont L, Guinard J, Guillaume C et al. High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection. Journal of Medical Virology 2021; 93: 3152-3157.

58 Drain P, Ampajwala M, Chappel C et al. A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious Diseases and Therapy 2021; 10: 753-761.

59 Favresse J, Gillot C, Oliveira M et al. Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. Journal of Clinical Medicine 2021; 10: 265.

60 Fenollar F, Bouam A, Ballouche M et al. Evaluation of the Panbio COVID-19 Rapid Antigen Detection Test Device for the Screening of Patients with COVID-19. Journal of Clinical Microbiology 2021; 59. DOI:10.1128/jcm.02589-20.

61 Gili A, Paggi R, Russo C et al. Evaluation of Lumipulse® G SARS-CoV-2 antigen assay automated test for detecting SARS-CoV-2 nucleocapsid protein (NP) in nasopharyngeal swabs for community and population screening. International Journal of Infectious Diseases 2021; 105: 391-396.

62 Ishii T, Sasaki M, Yamada K et al. Immunochromatography and chemiluminescent enzyme immunoassay for COVID-19 diagnosis. Journal of Infection and Chemotherapy 2021; 27: 915-918.

63 Gremmels H, Winkel B, Schuurman R et al. Real-life validation of the Panbio[™] COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. EClinicalMedicine 2021; 31: 100677.

64 Gupta A, Khurana S, Das R et al. Rapid chromatographic immunoassaybased evaluation of COVID-19: A cross-sectional, diagnostic test accuracy study & its implications for COVID-19 management in India. Indian Journal of Medical Research 2020; 0: 0.

65 Ciotti M, Maurici M, Pieri M, Andreoni M, Bernardini S. Performance of a rapid antigen test in the diagnosis of SARS-CoV-2 infection. Journal of Medical Virology 2021; 93: 2988-2991.

66 Hirotsu Y, Maejima M, Shibusawa M et al. Prospective study of 1308 nasopharyngeal swabs from 1033 patients using the LUMIPULSE SARS-CoV-2 antigen test: Comparison with RT-qPCR. International Journal of Infectious Diseases 2021; 105: 7-14.

67 Yamamoto K, Suzuki M, Yamada G et al. Utility of the antigen test for coronavirus disease 2019: Factors influencing the prediction of the possibility of disease transmission. International Journal of Infectious Diseases 2021; 104: 65-72.

68 Singanayagam A, Patel M, Charlett A et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Eurosurveillance 2020; 25. DOI:10.2807/1560-7917.es.2020.25.32.2001483.

69 Young B, Ong S, Ng L et al. Immunological and Viral Correlates of COVID-19 Disease Severity: A Prospective Cohort Study of the First 100 Patients in Singapore. SSRN Electronic Journal 2020. DOI:10.2139/ssrn.3576846.

70 Bullard J, Dust K, Funk D et al. Predicting Infectious Severe Acute

Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. Clinical Infectious Diseases 2020; 71: 2663-2666.

Can the Rapid Antigen Test for COVID-19 Replace RT-PCR: A Meta-analysis of Test Agreement Main Text's Tables and Figures

Table 1: Ct value range per group

Ct group	Ct range
Group 1	Ct <20
Group 2	Ct 20-30
Group 3	Ct >30
Group 4	Ct <25
Group 5	Ct <30

Figure 1: PRISMA flow-chart



Table 2: characteristics of included studies

Study	Design	Participants	Country	Numbe r of Ag- RDT per study	Ag-RDT description (company)	Gold standard description	Numb er of extrac -ted subgr oups	RT-PCR positive patients	Prev alen ce (%)	Source
Pena- Rodríguez et al (2021) ²⁹	Cross- sectional	369 adult volunteers, single centered, Sx and Asx	Mexico	1	STANDARD Q COVID-19 Ag (SD Biosensor)	DeCoV19 Kit Triplex	1	104	28.2	np
Pilarowski et al (2021) ³⁰	Cross- sectional	878 Sx and Asx in public plaza, San Francisco	USA	1	BinaxNOW COVID-19 RAT (Abbott)	RT-PCR against N and E genes (Chan Zuckerberg Biohub)	1	26	3	n
Pollock et al (2021) ³¹	Cross- sectional	2308 Sx and Asx adults and children, drive- through testing, Massachusetts	USA	1	BinaxNOW COVID-19 RAT (Abbott)	CRSP SARS-CoV- 2 RT-PCR	2	292	12.7	n
Pilarowski et al (2020) ³²	Cross- sectional	3302 Sx and Asx all ages in transport hub, San Francisco	USA	1	BinaxNOW COVID-19 RAT (Abbott)	RenegadeX P™ qRT- PCR	1	237	7.2	n
Albert et al (2021) ³³	Cross sectional	412 at primary healthcare centers, Sx	Spain	1	Panbio™ COVID-19 Ag Rapid Test (Abbott)	TaqPath COVID-19 Combo Kit	1	43	10.4	np
Aoki et al (December 23, 2020) ³⁴	Cross- sectional	129 samples, Sx and Asx hospitalized patients	Japan	1	Espline® SARS-CoV-2 rapid antigen test (Fujirebio)	BD MAX™, QuantStudio ® 5	1	63	48.8	np
Aoki et al (December 3, 2020) ³⁵	Cross- sectional	548 samples, Sx and Asx Omori Hospital	Japan	1	Lumipulse® SARS-CoV-2 Ag kit (Fujirebio)	BD MAX™, QuantStudio ® 5	1	24	4.4	np
Bulilete et al (2021) ³⁶	Cross- sectional	1369 Sx and Asx adults, 4 120 at primary	Spain	1	PanbioTM Ag- RDT (Abbott)	TaqPathTM , QuantStudio	2	140	10.2	np

		healthcare centers and 2 test sites				ТМ				
Ristic et al (2021) ³⁷	Cross- sectional	120 at primary healthcare center, Sx	Serbia	1	STANDARD Q COVID-19 Ag (SD Biosensor)	COVID-19 Genesig Real-Time PCR Kit	1	43	35.8	np
Möckel et al (2021)a ³⁸	Cross- sectional	271 Sx adults	German y	1	Roche SARS- CoV-2 rapid antigen test (Penzberg, Germany) (Roche)	SARS-CoV- 2 real-time reverse tran- scriptase (rt)-PCR diagnostic panel (PCRTEST)	1	89	41	np/op
Möckel et al (2021)b ³⁸	Cross- sectional	202 Sx pediatric	German y	1	Roche SARS- CoV-2 rapid antigen test (Penzberg, Germany) (Roche)	SARS-CoV- 2 real-time reverse tran- scriptase (rt)-PCR diagnostic panel (PCRTEST)	1	25	12.3	np/op
Merino et al (2021) ³⁹	Cross- sectional, prospective, multicentre	958 Sx and Asx (contact) from 10 independent hospitals	Spain	1	PanbioTM coronavirus disease 2019 (COVID-19) Ag Rapid Test Device (PanbioRT) (Abbott)	Each hospital has a different PCR kit, all are diagnostic	1	359	37.4	np
Nalumansi et al (2021) ⁴⁰	Cross- sectional, prospective, un-blinded	262 patients, Sx and Asx, all controls are volunteers!	Uganda	1	STANDARD Q COVID-19 Ag Test (SD Biosensor)	qRT-PCR (Berlin Protocol)	1	90	34.3	n
Osterman et al (2021) ⁴¹	Cross- sectional	Sx individuals in ED or clinical units of 2 different hospitals	German y	2	Roche Rapid Antigen Test, SD Biosensor Standard F COVID-19 Ag	RT-PCR, not specific kit (different swabs technics	2 (for each Ag- RDT)	445	53.5	n

						were used in different hospitals)				
Okoye et al (2021) ⁴²	Cross- sectional	2,645 Asx students presenting for screening at the University of Utah	USA	1	BinaxNOW COVID-19 RAT (Abbott)	Thermo Fisher TaqPath COVID-19 Combo kit	1	45	1.7	n
Young et al (2020) ⁴³	Cross- sectional	260 samples of Sx patients from 21 sites	USA	1	BD veritor (BD)	Lyra SARS- COV-2 assay	1	38	13.1	np/op
Villaverde et al (2021) ⁴⁴	Cross- sectional	1620 Sx pediatric patients (0-16y) from 7 centers	Spain	1	Panibo COVID Ag by Rapid Diagnostic (Abbott)	Variable Equipment among the 7 centers	1	77	4.8	np
Scohy et al (2021) ⁴⁵	Cross- sectional	148 Sx/Asx samples from Saint-Luc hospital (tertiary hospital)	Belgium	1	Coris COVID-19 Ag test, gembloux, belgium (Coris BioConcept)	Genesig RT PCR	2	106	71.6	np
Porte et al (2021) ⁴⁶	Cross- sectional	64 RT-PCR (+32, -32), Sx/Asx in a private medical centre	Chile	1	1- SOFIA SARS Antigen FIA (Quidel) 2- STANDARD F COVID-19 Ag FIA (SD Biosensor)	COVID-19 Genesig Real-Time PCR assay	2	32	50	np
Porte et al (2020) ⁴⁷	Cross- sectional	127 samples in a private medical centre, Sx and Asx (travel history or contact)	Chile	1	Bioeasy Biotechnology Co., Shenzhen, China; catalogue No. YRLF04401025, lot No. 2002N408 (Bioeasy)	COVID-19 Genesig Real-Time PCR assay	2	82	64.6	np/op
Pray et al (2021) ⁴⁸	Cross- sectional	1,098 paired samples Sx and Asx at two	USA	1	Sofia SARS Antigen Fluorescent	Uni A: CDC 2019-nCoV real-time	1	57	5.2	n

		university campuses- wisconsin			Immunoassay (FIA) (Quidel)	RT-PCR Uni B: TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific)				
Pérez et al (2021) ⁴⁹	Cross- sectional	320 consecutive NP from suspicious patients (- PCR:150 +PCR: 170). Sx/Asx	Spain	1	1- CerTest SARS-CoV-2 Ag (CerTest Biotec) 2- Panbio COVID- 19 Ag Rapid (Abbott)	1- Viasure SARS-CoV- 2 Real Time PCR Detection Kit 2- Allplex SARS-CoV- 2 assay 3- GeneFinder COVID-19 Plus RealAmp Kit	2	170	53.1	np
Prince et al (2021) ⁵⁰	Cross- sectional, retrospective	3,419 paired samples from Sx/Asx individuals and volunteers in two sites. Age from 10-95 years	USA	1	BinaxNOW COVID-19 Ag Card (Abbott)	1- CDC 2019-nCoV Real-Time RT-PCR 2- Fosun COVID-19 RT-PCR Detection Kit	1	299	8.7	n
Jääskeläin en et al (2021) ⁵¹	Cross- sectional study (case- control sampling)	158 positive and 40 negative retrospective samples were collected, including adults from outpatient setting. Sx	Finland	3	Sofia (Quidel), Standard Q (SD Biosensor), PanbioTM (Abbott)	Laboratory- developed RT-PCR (modified)	4 (for each RD- ADT)	158	79.8	np
Kobayashi et al (2021) ⁵²	Cross- sectional study (case- control sampling)	100 samples from 47 infected patients and 200 samples from healthy donors.	Japan	1	Lumipulse Presto SARS- CoV-2 Ag (Fujirebio)	RT-PCR "2019 Novel coronavirus detection kit" (Shimadzu	1	100	27	np

		Sx/Asx				Corporation, Kyoto, Japan).				
Kohmer et al (2021) ⁵³	Cross- sectional	100 Samples were collected from individuals in a shared living facility regardless of their clinical symptoms	German y	4	RIDA (R- Biopharm), SARS-CoV-2 RAT (Roche), NADAL (nal von minden), SARS- CoV-2 Ag Test (LumiraDx)	RT-PCR (Cobas 6800 system, roche diagnostics, focused on ORF1 gene)	4 (for each RD- ADT)	74	74	np
Krüttgen et al (2021) ⁵⁴	Cross- sectional study (case- control sampling)	75 swabs from positive patients and 75 swabs from negative patients, admitted in RWTH Aachen University hospital	German y	1	SARS-CoV-2 Rapid Antigen Test (Roche)	Real Star SARS-CoV- 2 RT-PCR Kit (Altona, Germany)	3	75	50	np
Linares et al (2020) ⁵⁵	Cross- sectional	255 nasopharyngeal swabs (150 from emergency department, 105 from primary helthcare centers), Sx and Asx	Spain	1	PanbioTM (Abbott)	RT-PCR, Hamilton Microlab Starlet for extraction and Allplex SARS-CoV- 2 assay for amplification	1	60	23.5	np
Chaimayo et al (2020) ⁵⁶	Cross- sectional	454 samples from suspected, contact individuals, pre- operative patients, Sx and Asx	Thailand	1	Standard™ Q COVID-19 Ag kit (SD Biosensor)	RT-PCR test, Allplex™ 2019-nCoV Assay	1	60	13.2	np/thro at
Courtellem ont et al (2021) ⁵⁷	Cross- sectional	121 Sx (infected/hospital ized), Asx 127 adults	France	1	COVID- VIRO antigen-based rapid detection test (AAZ-LMB)	TaqPath Covid-19 Multiplex RT-PCR,	2	121	48.8	np

						Thermo Fisher Scientific				
Drain et al (2021) ⁵⁸	Cohort, prospective	512 participants (Sx and Asx) from 10 sites in two countries	USA and UK	1	LumiraDx SARS-CoV-2 antigen test (LumiraDx)	Roche cobas SARS-CoV- 2 rt-PCR	1	123	24	np
Favresse et al (2021) ⁵⁹	Cross- sectional	118 Sx, 70 Asx	Belgium	4	Biotical (Biotical Health), Panbio (Abbott), Healgen (Healgen Scientific), and Roche (Roche)	RT-PCR LightCycler	5 (for each RD- ADT)	96	51.1	np
Fenollar et al (2021) ⁶⁰	Cross- sectional	182 Sx, 159 (Asx had contact with patients)	Marseille , France	1	Panbio COVID- 19 Ag rapid test device assay (Abbott)	VitaPCR SARS-CoV- 2 assay	5	204	59.8	np
Gili et al (2021)a ⁶¹	Cross- sectional	226 selected cohort	Umbria, Italy.	1	Lumipulse (Fujirebio)	AllplexTM SARS-CoV- 2 assay (Seegene, Seoul, South Korea).	1	95	42	np
Gili et al (2021)b ⁶¹	Cross- sectional	1738 screening cohort from Sx and close contact (Asx)	Umbria, Italy.	1	Lumipulse (Fujirebio)	AllplexTM SARS-CoV- 2 assay (Seegene, Seoul, South Korea).	1	90	5.5	np
Ishii et al (2021) ⁶²	Cross- sectional	33 COVID and 564 non COVID (486 nps and 136 saliva). Sx and Asx (contact)	Tokyo, Japan	2	Lumipulse test (Fujirebio), Espline test (nucleocapsid antigen) (Fujirebio)	RT-PCR, Ct 35	1 (for each RD- ADT)	24	4.9	np
Gremmels et al (2021)a ⁶³	Cross- sectional	1367 in Utrecht aged 16 and above, nearly all Sx	Netherla nds	1	PanbioTM COVID-19 Ag Rapid Test (Abbott),	RT-PCR	1	139	10	np

					nucleocapsid protein					
Gremmels et al (2021)b ⁶³	Cross- sectional	208 in Aruba aged 16 and above, nearly all Sx	Netherla nds	1	PanbioTM COVID-19 Ag Rapid Test (Abbott), nucleocapsid protein	RT-PCR	1	63	30	np
Gupta et al (2020) ⁶⁴	Cross- sectional	330 adults, Sx and Asx who had contact, conducted in a tertiary hospital	India	1	Standard Q rapid antigen detection test, nucleocapsidpro tein (SD Biosensor)	RT-PCR	1	77	23	np
Ciotti et al (2021) ⁶⁵	Cross- sectional	50 samples, suspected adults (15-94) of SARS- CoV-2 from a single hospital (symptomatic status not reported)	Rome, Italy	1	COVID-19 Ag Respi-Strip test (Coris BioConcept)	RT-PCR test, Qualitative Allplex™ 2019-nCoV Assay	1	39	78	np
Hirotsu et al (2021) ⁶⁶	Cross- sectional, prospective	1033 samples, Sx/Asx (age not reported)	Tokyo, Japan	1	Lumipulse SARS-CoV-2 Ag test (Fujirebio)	StepOnePlu s RT-PCR by Thermo Fisher Scientific	1	40	3.9	np
Yamamoto et al (2020) ⁶⁷	Retrospective observational study	229 samples form adults, single-center study of inpatients, Sx	Tokyo, Japan	1	Espline® SARS-CoV-2 rapid antigen test (Fujirebio)	Applied Biosystems 7500 Real- Time PCR System or QuantStudio 5	1	128	55.8	np

Sx=symptomatic. Asx=asymptomatic. np=nasopharyngeal. n=nasal. op=oropharyngeal.



Figure : NPA for Ag-RDTs





Pollock et al (2021) ³¹ Bulilete et al (2021) ³⁶ Merino et al (2021) ³⁶ Okoye et al (2021) ⁴² Scohy et al (2021) ⁴⁵ Porte et al (2021) ⁴⁶ Porte et al (2021) ⁴⁶ Porte et al (2021) ⁴⁷ Porte et al (2021) ⁴⁷ Porte et al (2021) ⁴⁷ Porte et al (2021) ⁴⁹ Pérez et al (2021) ⁴⁹ Pérez et al (2021) ⁴⁹ Pérez et al (2021) ⁵¹ Jääskeläinen et al (2021) ⁵¹ Jääskeläinen et al (2021) ⁵¹ StanDARD Q Párez et al (2021) ⁵¹ StanDARD Q Párez et al (2021) ⁵¹ Bioeasy Pérez et al (2021) ⁵¹ Bioeasy Pérez et al (2021) ⁵¹ Panbio Kohmer et al (2021) ⁵³ Rida	99.3 (96.3, 99.9) 87.1 (79.2, 92.3) 99.5 (97.0, 99.9) 95.8 (79.8, 99.3) 100.0 (72.2, 100.0) 100.0 (87.5, 100.0) 100.0 (87.5, 100.0) 100.0 (93.1, 100.0) 94.0 (86.8, 97.4) 96.4 (90.0, 98.8) 98.9 (93.9, 99.8) 99.0 (94.4, 99.8) 97.8 (92.4, 99.4)	9.29 7.62 11.33 1.98 1.17 2.35 2.35 3.93 5.46 5.46 5.46 5.46 5.23 5.65 5.39
Kohmer et al $(2021)^{53}$ NadalKohmer et al $(2021)^{53}$ LumiraDxKrüttgen et al $(2021)^{54}$ RocheFavresse et al $(2021)^{59}$ BioticalFavresse et al $(2021)^{59}$ PanbioFavresse et al $(2021)^{59}$ HealgenFavresse et al $(2021)^{59}$ RocheFavresse et al $(2021)^{59}$ RocheFonollar et al $(2021)^{60}$ PanbioOverall, QE $(1^2 = 50.1\%)$	93.8 (71.7, 98.9) 100.0 (80.6, 100.0) 87.5 (64.0, 96.5) 100.0 (80.6, 100.0) 93.0 (81.6, 100.0) 93.1 (83.6, 97.3) 93.1 (83.6, 97.3) 96.6 (88.3, 99.0) 96.6 (88.3, 99.0) 96.4 (91.1, 98.6) 96.8 (95.2, 98.0)	1.38 1.38 1.38 1.57 4.67 4.67 4.67 4.67 7.03 100.00

Figure 4: Forest plot for PPA of studies in group 4 Ct <25



Figure 5: Line plot for overall PPA across Ct groups